Nuclide Therapeutics secures over $6 million for drugs against treatment-resistance cancers
 Nuclide Therapeutics, a King’s College London spinout developing radioactive drugs to target therapy-resistant cancers, has closed a…
Venture capital’s mission to rearm the continent
European defense startups are attracting swathes of private capital, as investors look for exposure to an industry on…